SCC-Ag与宫颈癌新辅助化疗患者预后的相关性

Correlation of SCC-Ag and prognosis in patients with neoadjuvant chemotherapy for cervical cancer

目的:探索化疗前、后鳞状细胞癌抗原(SCC-Ag)及其变化对宫颈癌新辅助化疗患者预后的预测价值。方法:收集191例宫颈癌患者的临床资料,分析其预后情况与临床特征间的关系,探讨不同阶段SCC-Ag对预后的评估意义。结果:化疗反应、淋巴结转移及FIGO分期与预后呈现出一定的相关性(P<0.05),而年龄、绝经情况和组织分型与预后无关;化疗前SCC-Ag<2.8 ng/ml组5年生存率为89.47%,SCC-Ag≥2.8 ng/ml组为7 9.1 7%(P=0.0 4 8 4);化疗后SCC-Ag<0.9 ng/ml组5年生存率为90.32%,SCC-Ag≥0.9 ng/ml组为78.57%(P=0.023 8);SCC-Ag下降程度≥50%和<50%之间比较差异无统计学意义。结论:化疗前和化疗后的SCC-Ag水平对宫颈癌新辅助化疗患者预后有一定的评估价值。

Objective： To explore the prognostic value of SCC-Ag in patients with neoadjuvant chemotherapy for cervical cancer in pre-chemotherapy,post-chemotherapy and the change between them. Methods： Collecting 191 cases of cervical cancer patients with clinical information,studying the relationship between the prognosis and the clinical features,exploring the significance of SCC-Ag in different stages for prognosis. Results： Chemotherapy response,lymph node metastasis and FIGO stage showed some correlation with prognosis（ P 〈0. 05）,but age,menopausal status and histological classification had nothing to do with prognosis. The 5-year survival rate of SCC-Ag 〈2. 8 ng/ml and SCC-Ag≥2. 8 ng/ml before chemotherapy were 89. 47% and 79. 17%（ P = 0. 048 4）. The 5-year survival rate of SCC-Ag 0. 9 ng/ml and SCC-Ag≥0. 9 ng/ml after chemotherapy were 90. 32% and 78. 57%（ P = 0. 023 8）.There was no significant difference in the reduction of SCC-Ag ≥50% and 〈50%. Conclusion： The SCC-Ag level before and after chemotherapy have a certain value in evaluating the prognosis in patients with neoadjuvant chemotherapy for cervical cancer.